Quality assessment of genetic markers used for therapy stratification

Journal of Clinical Oncology

Volumn 21, Issue 11, 2003, Pages 2077-2084

  Ambros, Inge M ^a   Benard, J ^b   Boavida, M ^b   Bown, N ^b   Caron, H ^b   Combaret, V ^b   Couturier, J ^b   Darnfors, C ^b   Delattre, O ^b   Freeman Edward, J ^b   Gambini, C ^b   Gross, N ^b   Hattinger, C M ^b   Luegmayr, A ^b   Lunec, J ^b   Martinsson, T ^b   Mazzocco, K ^b   Navarro, S ^b   Noguera, R ^b   O'Neill, S ^b   Potschger U ^b   Rumpler, S ^b   Speleman, F ^b   Tonini, G P ^b   Valent, A ^b   Van Roy, N ^b   Amann, G ^b   De Bernardi, B ^b   Kogner, P ^b   Ladenstein, R ^b   Michon, J ^b   Pearson, A D J ^b   Ambros, Peter F ^a   more..

^a CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEAR PROTEIN; PROTEIN MYCN; UNCLASSIFIED DRUG; DNA; MYCN PROTEIN, HUMAN; ONCOPROTEIN; TUMOR MARKER;

ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; GENETIC MARKER; GENETIC TRAIT; HUMAN; HUMAN TISSUE; IMAGE CYTOMETRY; IN SITU HYBRIDIZATION; LABORATORY TEST; MAJOR CLINICAL STUDY; MEDICAL ERROR; MEDICAL SOCIETY; NEURINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; QUALITY CONTROL; SOUTHERN BLOTTING; STRATIFICATION; CHROMOSOME 1; CLINICAL TRIAL; COMPARATIVE STUDY; DIAGNOSTIC ERROR; EUROPE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC PROCEDURES; GENETICS; HEALTH CARE QUALITY; MULTICENTER STUDY; NEUROBLASTOMA; NOMENCLATURE; PATHOLOGY; PLOIDY; POLYMERASE CHAIN REACTION; STANDARD; STATISTICS;

BLOTTING, SOUTHERN; CHROMOSOMES, HUMAN, PAIR 1; DIAGNOSTIC ERRORS; DNA, NEOPLASM; EUROPE; GENETIC TECHNIQUES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PLOIDIES; POLYMERASE CHAIN REACTION; QUALITY ASSURANCE, HEALTH CARE; QUALITY CONTROL; REFERENCE STANDARDS; TERMINOLOGY; TUMOR MARKERS, BIOLOGICAL;

EID: 0037601662     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.03.025     Document Type: Article

References (34)

1. Shimada H, Ambros IM, Dehner LP, et al: The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86:364-372, 1999
2. Shimada H, Ambros IM, Dehner LP, et al: Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 86:349-363, 1999
3. Matthay KK, Sather HN, Seeger RC, et al: Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol 7:236-244, 1989
4. Kushner BH, Cheung NK, LaQuaglia MP, et al: Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. J Clin Oncol 14:373-381, 1996
5. Ambros PF, Ambros IM, Strehl S, et al: Regression and progression in neuroblastoma: Does genetics predict tumour behaviour? Eur J Cancer 31A:510-515, 1995
6. Brodeur GM, Nakagawara A: Molecular basis of clinical heterogeneity in neuroblastoma. Am J Pediatr Hematol Oncol 14:111-116, 1992
7. Ambros IM, Zellner A, Roald B, et al: Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma. N Engl J Med 334:1505-1511, 1996
8. Bown N, Cotterill S, Lastowska M, et al: Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 340:1954-1961, 1999
9. Brodeur GM, Ambros PF: Genetic and biological markers of prognosis in neuroblastoma, in Brodeur GM, Sawada T, Tsuchida Y, et al (eds): Neuroblastoma. Amsterdam, the Netherlands, Elsevier, 2000, pp 355-369
10. Schwab M, Alitalo K, Klempnauer KH, et al: Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305:245-248, 1983
11. Brodeur GM, Seeger RC, Schwab M, et al: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224:1121-1124, 1984
12. Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313:1111-1116, 1985
13. Douglass EC, Green AA, Hayes FA, et al: Chromosome 1 abnormalities: A common feature of pediatric solid tumors. J Natl Cancer Inst 75:51-54, 1985
14. Stock C, Ambros IM, Mann G, et al: Detection of Ip36 deletions in paraffin sections of neuroblastoma tissues. Genes Chromosomes Cancer 6:1-9, 1993
15. Schleiermacher G, Delattre O, Peter M, et al: Clinical relevance of loss heterozygosity of the short arm of chromosome 1 in neuroblastoma: A single-institution study. Int J Cancer 69:73-78, 1996
16. Caron H, van Sluis P, de Kraker J, et al: Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 334:225-230, 1996
17. Kaneko Y, Kanda N, Maseki N, et al: Different karyotypic patterns in early and advanced stage neuroblastomas. Cancer Res 47:311-318, 1987
18. Fong CT, White PS, Peterson K, et al: Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res 52:1780-1785, 1992
19. Maris JM, White PS, Beltinger CP, et al: Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res 55:4664-4669, 1995
20. Gehring M, Berthold F, Edler L, et al: The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. Cancer Res 55:5366-5369, 1995
21. Bourhis J, De Vathaire F, Wilson GD, et al: Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Cancer Res 51:33-36, 1991
22. Look AT, Hayes FA, Shuster JJ, et al: Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 9:581-591, 1991
23. Ladenstein R, Ambros IM, Potschger U, et al: Prognostic significance of DNA di-tetraploidy in neuroblastoma. Med Pediatr Oncol 36:83-92, 2001
24. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993
25. Rubie H, Hartmann O, Michon J, et al: N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: Results of the French NBL 90 study- Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 15:1171-1182, 1997
26. Shimada H, Chatten J, Newton-WA J, et al: Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 73:405-416, 1984
27. Joshi VV, Rao PV, Cantor AB, et al: Modified histologic grading of neuroblastomas by replacement of mitotic rate with mitosis karyorrhexis index: A clinicopathologic study of 223 cases from the Pediatric Oncology Group. Cancer 77:1582-1588, 1996
28. Ambros PF, Ambros IM: Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol 37:492-504, 2001
29. Dewald GW, Stallard R, Bader PI, et al: Toward quality assurance for metaphase FISH: A multicenter experience. Am J Med Genet 65:190-196, 1996
30. Schweiger B, Pauli G, Zeichhardt H, et al: A multicentre quality assessment study to monitor the performance of HIV-1 PCR. J Virol Methods 67:45-55, 1997
31. Dequeker E, Cassiman JJ: Genetic testing and quality control in diagnostic laboratories. Nat Genet 25:259-260, 2000
32. Tirindelli DD, Spano M, Altavista P, et al: Quality control study of the Italian Group of Cytometry on flow cytometry DNA content measurements: II. Factors affecting inter- and intralaboratory variability. Cytometry 30:85-97, 1997
33. D'hautcourt JL, Spyratos F, Chassevent A: Quality control study by the French Cytometry Association on flow cytometric DNA content and S-phase fraction (S%): The Association Francaise de Cytometrie. Cytometry 26:32-39, 1996
34. Danesi DT, Spano M, Altavista P: Quality control study of the Italian group of cytometry on flow cytometry cellular DNA content measurements. Cytometry 14:576-583, 1993